Amicus Therapeutics’ Galafold (migalastat) Receives FDA Approval for Fabry Disease in Adult Patients

Shots:

• The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease, evaluating its safety and efficacy
• The FACET or Study 011 resulted in reduction of substrate (KIC GL-3) accumulation in the kidney capillaries
• Galafold (migalastat) 123mg is a novel PO dosage form of alpha Galactosidase A used for Fabry Disease in adults and is approved in the US, EU, Australia, Canada, Israel, Japan, South Korea & Switzerland

Click here to read full press release/ article | Ref: Amicus Therapeutics | Image: Reuters